TY - JOUR T1 - Haematopoietic stem cell transplantation in systemic sclerosis JF - RMD Open JO - RMD Open DO - 10.1136/rmdopen-2017-000533 VL - 4 IS - 1 SP - e000533 AU - Ulrich A Walker AU - Lesley Ann Saketkoo AU - Oliver Distler Y1 - 2018/06/01 UR - http://rmdopen.bmj.com/content/4/1/e000533.abstract N2 - Three randomised controlled trials of haematopoietic stem cell transplantation (HSCT) in systemic sclerosis (SSc) demonstrated long-term survival benefits, induction of clinically meaningful, sustained improvement of forced vital capacity with improvements in skin thickening, vasculopathy and health-related quality of life, in contrast to a clinical decline in standard of care control groups. These benefits, however, must be weighed against the increased risk of transplant-related mortality. Further, with disease progression, severe extensive internal organ involvement and damage ensues, constituting an exclusion criterion for safety reasons, leaving a limited window whereby patients with SSc are eligible for HSCT. Although autologous HSCT offers the possibility of drug-free remission, relapse can occur, requiring re-initiation of disease modifying antirheumatic drugs. HSCT is also associated with secondary autoimmune diseases and gonadal failure. HSCT should be proposed for carefully selected patients with early rapidly progressive diffuse SSc whose clinical picture portends a poor prognosis for survival, but yet lacks advanced organ involvement. ER -